In Phase A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to identify Risk-free dosing program. Added contributors is going to be enrolled with the discovered monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase https://abbv-744clinicaltrialphas35679.bloggosite.com/38642596/abbv-744-cancer-treatment-clinical-trials-an-overview